Hepatobiliary carcinoma
Conditions
Interventions
SBRT combined with low-dose radiotherapy + targeted immunotherapy:low-dose radiotherapy
targeted immunotherapy
SBRT combined with low-dose radiotherapy + targeted immunotherapy + polyinosinic-polycytidylic acid:low-dose radiotherapy
targeted immunotherapy
Polymyocytoid injection is injected subcutaneously in t
Sponsors
Mengchao Hepatobiliary Hospital of Fujian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. voluntarily enrolled in this study and signed an informed consent form; 2. aged 18-75 years old, male or female; 3. patients with unresectable intermediate and advanced hepatocellular carcinoma with multiple foci diagnosed by imaging (CT/MRI) or histopathological/cytological examination, with disease progression or treatment resistance after previous local treatment (TACE/HAIC) and/or first-line systemic therapy; 4. have at least 1 imaging measurable lesion according to the solid tumour efficacy evaluation criteria RECIST v1.1; 5. fulfil the following biochemical parameters: creatinine clearance >= 60 ml/min, child-pugh grade A to B; 6. Expected survival >= 6 months; 7. Meet other indications for receiving radiotherapy.
Exclusion criteria
Exclusion criteria: 1. patients with HIV infection, uncontrollable coronary artery disease or asthma, uncontrollable cerebrovascular disease, or other conditions deemed by the investigator to be ineligible for enrolment; 2. patients with a history of bone marrow or organ transplantation; 3. patients with secondary brain metastases; 4. subjects with immunodeficiency diseases or autoimmune diseases; 5. Those who are clearly allergic or potentially allergic to, or intolerant of, the components of Polymyxin Injection, Immune Checkpoint Inhibitors; 6. Pregnant or lactating women; 7. Substance abuse, clinical or psychological or social factors that compromise informed consent or study conduct; 8. any uncertainty that has an impact on patient safety or compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Duration of remission;Time to treatment remission;Disease control rate;9-month survival rate;12-month survival rate;overall survival; | — |
Countries
China
Contacts
Public ContactJi Hongbing
Mengchao Hepatobiliary Hospital of Fujian Medical University
Outcome results
None listed